Prescribe colchicine with care and be aware of colchicine drug interactions.

Colchicine has multiple anti-inflammatory properties and is used for a variety of disorders. As the use of colchicine expands from its approved uses (e.g. gout) to various off-label indications (e.g. pericarditis), the risk for drug–drug interactions (DDIs) to occur with colchicine increases. Colchicine is a substrate for cytochrome P450 3A4 (CYP3A4) and permeability glycoprotein (P-gp) and, when used concurrently with other CYP3A4 and/or P-gp inhibitors, can lead to life-threatening outcomes. This article summarises the risks associated with colchicine use, mechanisms behind adverse DDIs and various management options to minimise patient harm from colchicine DDIs. [ABSTRACT FROM AUTHOR]